Sinovac Biotech Ltd. Files November 2025 6-K Report
Ticker: SVA · Form: 6-K · Filed: Nov 5, 2025
Sentiment: neutral
Topics: sec-filing, 6-k, foreign-issuer
TL;DR
Sinovac Biotech filed its monthly 6-K report for November 2025, standard procedure for foreign issuers.
AI Summary
Sinovac Biotech Ltd. filed a Form 6-K on November 5, 2025, reporting for the month of November 2025. The company, headquartered in Beijing, China, is a pharmaceutical preparations company. This filing is a routine report for a foreign private issuer.
Why It Matters
This filing provides routine updates for investors and regulators regarding Sinovac Biotech Ltd.'s status as a foreign private issuer.
Risk Assessment
Risk Level: low — This is a routine filing and does not contain new financial or operational information that would typically impact risk.
Key Players & Entities
- Sinovac Biotech Ltd. (company) — Filer of the report
- 001-32371 (other) — Commission File Number
- 20251105 (date) — Conformed period of report
- 20260130 (date) — Date as of change
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the issuer has made or is required to make public pursuant to the laws of its home country, or that it has filed or will file with a stock exchange on which it has securities listed.
What period does this specific 6-K filing cover?
This Form 6-K filing is for the month of November 2025, with a conformed period of report date of November 5, 2025.
Where is Sinovac Biotech Ltd. headquartered?
Sinovac Biotech Ltd. is headquartered at No. 39 Shangdi Xi Rd, Haidian District, Beijing 100085, People's Republic of China.
Does Sinovac Biotech Ltd. file annual reports under Form 20-F or Form 40-F?
Sinovac Biotech Ltd. indicates that it files annual reports under cover of Form 20-F.
What is the SIC code for Sinovac Biotech Ltd.?
The Standard Industrial Classification (SIC) code for Sinovac Biotech Ltd. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 161 words · 1 min read · ~1 pages · Grade level 11.2 · Accepted 2026-01-30 15:24:02
Filing Documents
- ea0263581-6k_sinovac.htm (6-K) — 9KB
- ea026358101ex99-1_sinovac.htm (EX-99.1) — 9KB
- 0001213900-25-106469.txt ( ) — 19KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2025 --------------- Commission File Number: 001-32371 --------------- SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Rd, Haidian District Beijing 100085, People’s Republic of China (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SINOVAC BIOTECH LTD. By: /s/ Sven H. Borho Name: Mr. Sven H. Borho Title: Director & Chair of Audit Committee Date: November 5, 2025 1 Exhibit Index Exhibit 99.1 Press Release – SINOVAC Announces Appointment of Independent Auditor 2